期刊
CURRENT OPINION IN RHEUMATOLOGY
卷 22, 期 5, 页码 499-503出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0b013e32833c62b0
关键词
autoimmunity; interleukin-17; systemic lupus erythematosus
类别
资金
- National Institutes of Health [R01 AI043043, RO1AI85567]
- Arthritis Foundation
- Mary Kirkland Center for Lupus Research
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI085567] Funding Source: NIH RePORTER
Purpose of review Interleukin-17 (IL-17) has emerged as a key cytokine involved in the pathogenesis of autoimmune diseases. In this article, we review recently produced evidence obtained in patients and murine models of lupus that link increased IL-17 production with lupus pathology and discuss the potential roles IL-17 may play in the pathogenesis of systemic lupus erythematosus. Recent findings IL-17 may promote autoantibody production and IL-17-producing cells are found in afflicted organs in humans and lupus-prone mice. T(H)17 and CD3(+)CD4(-)CD8(-) cells are expanded in systemic lupus erythematosus patients and account for the increased production of IL-17. Genetic silencing of genes involved in the increased production of IL-17 in lupus-prone mice as well as treatment of mice with lupus using biologic agents that result in decreased IL-17 production leads invariably to disease mitigation. Summary The presented evidence strongly argues for the introduction of IL-17-suppressing biologics in the treatment of patients with systemic lupus erythematosus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据